Provided by Tiger Trade Technology Pte. Ltd.

PagerDuty, Inc.

6.31
-0.0200-0.32%
Volume:2.37M
Turnover:15.02M
Market Cap:536.22M
PE:3.37
High:6.52
Open:6.27
Low:6.23
Close:6.33
52wk High:19.68
52wk Low:6.15
Shares:84.98M
Float Shares:80.63M
Volume Ratio:0.74
T/O Rate:2.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.87
EPS(LYR):1.87
ROE:82.50%
ROA:0.48%
PB:2.11
PE(LYR):3.37

Loading ...

PagerDuty price target lowered to $6 from $12 at BofA

TIPRANKS
·
Mar 13

PagerDuty (PD) Gets a Hold from Craig-Hallum

TIPRANKS
·
Mar 13

Wall Street Set to Open Higher Friday as Investors Parse Inflation Data, Oil Prices

MT Newswires Live
·
Mar 13

RBC Capital Remains a Hold on PagerDuty (PD)

TIPRANKS
·
Mar 13

Top Premarket Decliners

MT Newswires Live
·
Mar 13

Press Release: AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update

Dow Jones
·
Mar 13

PagerDuty Inc : TD Cowen Cuts Target Price to $10 From $20

THOMSON REUTERS
·
Mar 13

Truist Cuts Price Target on PagerDuty to $9 From $12, Keeps Buy Rating

MT Newswires Live
·
Mar 13

PagerDuty Shares Slide on Weak Outlook

Dow Jones
·
Mar 13

PagerDuty (PD) was downgraded to a Hold Rating at William Blair

TIPRANKS
·
Mar 13

PagerDuty Fiscal Q4 Non-GAAP Earnings, Revenue Increase

MT Newswires Live
·
Mar 13

BioVie Announces Abstract Accepted for Presentation at AD/PD 2026

GlobeNewswire
·
Mar 12

Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update

GlobeNewswire
·
Mar 12

CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference

GlobeNewswire
·
Mar 12

Press Release: Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Dow Jones
·
Mar 12

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

GlobeNewswire
·
Mar 11

SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

GlobeNewswire
·
Mar 10

Press Release: Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Dow Jones
·
Mar 10

CSTONE PHARMA-B Surges Over 12% on Promising Prospects for Major Business Development Deal for its Proprietary Tri-Specific Antibody

Stock News
·
Mar 05

Market Chatter: PagerDuty CEO Tejada Says AI Disruption Concerns 'Overbaked'

MT Newswires Live
·
Mar 05